The role of somatostatin in the pathophysiology of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 16, Issue 6, 1998, Pages 745-749

  Sakane, T ^a   Suzuki, N ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Neuropeptides; Rheumatoid arthritis; Somatostatin; Somatostatin receptor; Synovial cells

Indexed keywords

MATRIX METALLOPROTEINASE; NEUROPEPTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CELL INTERACTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; MOLECULAR INTERACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; HUMANS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SYNOVIAL MEMBRANE;

EID: 0031732476     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. HARRIS ED Jr: Rheumatoid arthritis: Pathophysiology and implications for therapy. N EnglJMed 1990; 322: 1277-89.
2. CASH JM, KLIPPEL JH: Second-line drug therapy for rheumatoid arthritis. NEnglJAfed 1994; 330: 1368-75.
3. FELDMANN M, BRENNAN FM, MAINI RN: Rheumatoid arthritis. Cell 1996; 85:307-10.
4. WILDER RL: Neuroendocrine-immune system interactions and zuloimmunily. Anmi Rev Immunol 1995; 13:307-38.
5. McCARTYDJ,KOOPMANWJ(Eds.):/lr//in/ii and Allied Conditions: A Textbook of Rheumatology, 12th ed., Philadelphia, Lea and Febiger, 1993.
6. HABENER JF, MEYER TE, YUN Y, WAEBER G, HOEFFLER JP: Characterization of a cAMPregulated enhancer-binding protein. Metabolism 1990; 39 (Suppl. 2): 13-6.
7. GRÖNBLAD M, KONTTINEN YT, KORKALA O, LIESI P, HUKKANEN M, POLAK JM: Neuropeptides in synovium of patients with rheumatoid arthritis and osteoarthritis.7Rheiimatol 1988; 15: 1807-10.
8. WALSII DA, MAPP PI, WHARTON J, POLAK JM, BLAKE DR: Neuropeptide degrading enzymes in normal and inflamed human synovium. Am J Pathol 1993; 142:1610-21.
9. LOTZ M, CARSON DA, VAUGHAN JH: Substance P activation of rheumatoid synoviocytes: Neural pathway in pathogenesis of arthritis. Science 1987; 235:893-5.
10. BRAZEAU P, VALE W, BURGUS R, et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
11. VALE W, LING N, RIVIER J, et al.: Anatomic and phylogenetic distribution of somatostatin. Metabolism 1976; 25 (Suppl. 1): 1491-4.
12. GAUDILLERE A, MISERY L, BERNARD C, SOUCHIER C, CLAUDY A, SCHMITT D: Près-ence of somatostatin in normal human epidermis. BrJDermatol 1997; 137: 376-80.
13. KARALIS K, MASTORAKOS G, CHROUSOS GP, TO LIS G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin In' vest 1994; 93: 2000-6.
14. KIMATA H, YOSHIDA A, FUJIMOTO M, MIKAWA H: Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. J Immunol 1993; 150:4630-40.
15. PAYAN DG, HESS CA, GOETZL EJ: Inhibition by somatostatin of the proliferation of Tlymphocytes and Molt-4 lymphoblasts. Cell Immunol 1984; 84: 433-8.
16. GOETZL EJ, PAYAN DG: Inhibition by somatostatin of the release of mediators from human basophils and rat leukemic basophils. J Immunol 1984; 133: 3255-9.
17. KARALIS K, MASTORAKOS G, SANO H, WILDER RL, CHROUSOS GP: Somatostatin may participate in the antiinflammatory actions of glucocorticoids. Endocrinology 1995; 136:4133-8.
18. SICUTERI F, GEPPETTI P, MARADINI S, LEMBECK F: Pain relief by somatostatin in attacks of cluster headache. Pain 1984; 18: 359-65.
19. CHRUBASIK J, MEYNADIER J, BLOND S, et al.: Somatostatin, a potent analgesic. Lancet 1984; II: 1208-9.
20. MATUCCI-CERINIC M, LOTTI T, CAPPUGI P, BODDI V, FATTORINI L, PANCONESI E: Somatostatin treatment of psoriatic arthritis. Int J Derm 1988; 27: 56-8.
21. MATUCCI-CERINIC M, MARABINI S: Somatostatin treatment for pain in rheumatoid arthritis: A double blind versus placebo study in knee involvement. MedSciRes 1988; 16: 233-4.
22. CANDI E, MELINO G, DELAURENZI V, et al: Tamoxifen and somatostatin affect tumors by inducing apoptosis. Cancer Lett 1995; 96: 141-5.
23. MATUCCI-CERINIC M, BORRELLI F, GENERINI S, et al.: Somatostatin-induced modulation of inflammation in experimental arthritis. Arthritis Rheum 1995; 38:1687-93.
24. COARI G, DI FRANCO M, IAGNOCCO A, DI NOVI MR, MAUCERI MT, CIOCCI A: Intra-articular somatostatin 14 reduces synovial thickness in rheumatoid arthritis: An ultrasonographic study. lut J Clin Pharm Res 1995; 15: 27-32.
25. FIORAVANTI A, GOVONI M, LA MONTAGNA G, étal.: Somatostatin 14 and joint inflammation: evidence for intra-articular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exptl Clin Res 1995; 21:97-103.
26. SILVERI F, LO-BARCO C, BRECCIAROLI D: Somatostatin in peri-arthropathies of the shoulder: Clinical effectiveness and tolerability after sub-acromial administration. Clin Ter 1997; 148: 75-81.
27. RUSSO S, MANGRELLA M, VITAGLIANO S, RUSSO P, BERRINO L: Local administration of somatostatin in joint diseases in athletes. Minen-aMed 1997; 88: 265-70.
28. SCHAFFER K, HERRMUTH H, MUELLER J, et al.: Bombesin-like peptides stimulate somatostatin release from rat fundic D cells in pri-mary culture./lm JPhysiol 1997; 273: G68695.
29. BELL GI, YASUDA K, KONG H, LAW SF, RAYNOR K, REISINET: Molecular biology of somatostatin receptors. Ciba Found Symp 1995; 190:65-88.
30. REUBI JC, WASER B, MARKUSSE HM, KRENNING EP, VANHAGEN M, LAISSUE JA: Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. EurJ Plmrmacol 1994; 271: 371-8.
31. VANHAGEN PM, MARKUSSE HM, LAMBERTS SWJ, KWEKKEBOOM DJ, REUBI JC, KRENNING EP: Somatostatin receptor imaging: the presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 1994; 37: 1521-7.
32. DE BOIS MH, PAUWELS EK, BREEDVELD FC: New agents for scintigraphy in rheumatoid arthritis. EurJNuclMcd 1995; 22:133946.
33. VAN HAGEN PM: Somatostatin receptor expression in clinical immunology. Metabolism 1996; 45 (8 Suppl. 1): 86-7.
34. PATEL YC, MURTHY KK, ESCHER EE, BANVILLE D, SPIESS J, SRIKANT CB: Mechanism of action of somatostatin: An overview of receptor function and studies of the molecu-lar characterization and purification of somatostatin receptor proteins. Metabolism 1990; 39 (Suppl. 2): 63-9.
35. REISINE T: Somatostatin desensitization: Loss of the ability of somatostatin to inhibit cyclic AMP accumulation and adrenocorticotropin hormone release. J PharmacolExp Tlier 1983; 229: 14-20.
36. SRIKANT CB, SHEN SH: Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996; 137: 3461-8.
37. CORDELIER P, ESTEVE JP, BOUSQUET C, et al.: Characterization of the anti-proliferative signal mediated by the somatostatin receptor subtype sst5. Proc Nail Acad Sei USA 1997; 94: 9343-8.
38. FEWELL JW, KUFF EL: Intracellular redistribution of Ku immunoreactivity in response to cell-cell contact and growth modulating components in the medium. J Cell Sei 1996; 109:1937-46.
39. MOORADIAN DL, FERNANDES B, DIGLIO ÇA, LESTER BR: Angiopeptin (BIM23014C) inhibits vascular smooth muscle cell migration in vitro through a G-protein-mediated pathway and is associated with inhibition of adenylyl cyclase and cyclic AMP accumulation. J Cardiovasc Pharmacol 1995; 25:6118.
40. HOFLAND LJ, LAMBERTS SW: Somatostatin receptors and disease: Role of receptor subtypes. Baillières Clin Endocrinol Metab 1996; 10:163-76.
41. COY DH, TAYLOR JE: Receptor-specific somatostatin analogs: Correlations with biological activity. Metabolism 1996; 45: 21-3.
42. LORENZ JJ, FURDON PJ, TAYLOR JD, Cl al. : A cyclic adenosine 3',5'-monophosphate signal is required for the induction of IL-l by TNFct in human monocytes../Immunol 1995; 155: 836-44.
43. DAYER J-M, DE ROCHEMONTEIX B, BURRUS B, DEMCZUK S, DINARELLO CA: Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovia! cells. J Clin Invest 1986; 77: 645-8.
44. MEYER FA, YARON I, YARON M: Synergistic, additive, and antagonistic effects of interleukin-l, tumor necrosis factor a, and y-interferon on prostaglandin E, hyaluronic acid, and collagenase production by cultured synovial fibroblasts. Arthritis Rheum 1990; 33: 151825.